Analyst Reco. Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
16.19 ^USD	-2.41%		+16.14%	+56.88%

May. 20	Nurix Therapeutics Names New Board Chair	MT
May. 14	Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stephens Initiates Nurix Therapeutics With Overweight Rating, $20 Price Target	May. 14	MT
Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share	Apr. 12	MT
Baird Adjusts Price Target on Nurix Therapeutics to $25 From $24, Maintains Outperform Rating	Apr. 11	MT
RBC Lifts Price Target on Nurix Therapeutics to $23 From $22, Keeps Outperform Rating, Speculative Risk Qualifier	Apr. 11	MT
Morgan Stanley Adjusts Nurix Therapeutics' Price Target to $10 From $9, Keeps Equalweight Rating	Feb. 26	MT
HC Wainwright Cuts Nurix Therapeutics Price Target to $19 From $35, Maintains Buy Rating	Feb. 20	MT
RBC Cuts Price Target on Nurix Therapeutics to $22 From $24, Keeps Outperform, Speculative Risk	Feb. 16	MT
RBC Cuts Price Target on Nurix Therapeutics to $24 From $29, Keeps Outperform, Speculative Risk	Nov. 02	MT
RBC Trims Price Target on Nurix Therapeutics to $29 From $30, Keeps Outperform, Speculative Risk	23-10-13	MT
HC Wainwright Adjusts Price Target on Nurix Therapeutics to $35 From $33, Keeps Buy Rating	23-09-08	MT
HC Wainwright Adjusts Nurix Therapeutics Price Target to $33 From $53, Maintains Buy Rating	23-07-24	MT
Morgan Stanley Adjusts Price Target on Nurix Therapeutics to $12 From $11, Maintains Equal-Weight Rating	23-07-17	MT
Barclays Initiates Nurix Therapeutics at Overweight With $20 Price Target	23-03-09	MT
Oppenheimer Initiates Coverage on Nurix Therapeutics With Outperform Rating, $25 Price Target	23-02-28	MT
Stifel Adjusts Price Target on Nurix Therapeutics to $31 From $37, Maintains Buy Rating	23-02-14	MT
JPMorgan Chase Adjusts Price Target on Nurix Therapeutics to $36 From $37, Maintains Overweight Rating	23-02-13	MT
Berenberg Bank Adjusts Nurix Therapeutics' Price Target to $30 From $48, Maintains Buy Rating	23-02-13	MT
Needham Trims Price Target on Nurix Therapeutics to $31 From $32, Maintains Buy Rating	23-02-10	MT
RBC Cuts Price Target on Nurix Therapeutics to $30 From $39, Maintains Outperform, Speculative Risk	23-02-10	MT
Morgan Stanley Starts Nurix Therapeutics at Equalweight with $11 Price Target	22-10-11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Analyst Reco.

Filters